Daily Roundup

CCA.ASX ALC.ASX BOT.ASX CDA.ASX EYE.ASX

Strong Q3 Results Across ASX-Listed Companies

Change Financial delivered an impressive Q3, with record quarterly customer receipts, increased revenue, and significantly higher Underlying EBITDA. The company's Vertexon platform continues to scale, and it signed two new PaaS clients in Australia during the quarter. Change reaffirmed its FY26 guidance and remains focused on building its sales pipeline and driving operational efficiencies.

Alcidion Group also had a solid quarter, reporting positive operating cashflow of $1.7 million driven by cash receipts of $14.5 million. The company secured $11.7 million in new TCV sales, including contract expansions and new deals. Alcidion was also selected as the preferred provider for the University Hospital Sussex NHS Foundation Trust's new EPR solution. The company reconfirmed its FY26 guidance of revenue exceeding $50 million and EBITDA over $5 million.

Botanix Pharmaceuticals saw a 5% increase in total prescriptions shipped for Sofdra during Q3 FY26. However, the company experienced a temporary decline in average gross-to-net yield due to the annual deductible reset. Botanix successfully raised $45 million through a capital raising and renegotiated its API supply agreement to defer $15 million in purchases over future years.

Codan Ltd provided a strong trading update for FY26, indicating that its Communications business is expected to achieve revenue growth at the top end of the 15-20% range. The company also expects the Communications segment profit margin to outperform the 30% target, reaching 30% in FY26. Minelab revenue is also tracking ahead of the strong first-half performance. As a result, Codan now expects EBIT and NPAT to increase by over 60% versus FY25.

Finally, Nova Eye Medical reported a 23% increase in quarterly sales to US$5.8 million, driven by continued momentum in the US and first sales in China. The company also achieved a material improvement in EBITDA, with a loss of just US$75,000 compared to US$482,000 in the prior period. Nova Eye has updated its FY26 sales guidance (excluding China) to be between US$21 million and US$22 million and reaffirmed its expectation of breakeven or a small positive EBITDA in the second half of FY26.

Overall, it's been a strong quarter for these ASX-listed companies, with impressive financial results, new client wins, and positive outlooks for the year ahead.